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8 Oral PresentationsTable 1. Cumulative incidence of AGVHD, NRM and Relapse
according to HLA typing and kind of conditioning
RIC Std11HLA siblings
AGVHD (D100) Gr I 15% [9-20,5] 34% [19-49]
Gr II 15% [9-21,4] 9,5% [7-49]
Gr III-IV 11% [6-16] 12% [2-22]
NRM at 1 year 8,4% [12-25] 23% [11-35.6]
Relapse at 1 year 13% [8 -19] 6% [0-14]Unrelated Donors
AGVHD (D100) Gr I 13% [6-20] 22% [4-39]
Gr II 22% [13-30] 26% [7,5-45]
Gr III-IV 14% [7-21] 22% [4-39]
NRM at 1 year 24% [16-32] 36% [17-55]
Relapse at 1 year 16% [9-23] 4% [0-12]The CI of lim. and ext. cGVHD at 1 yr, were 15 % (6–24) and
29.5% (18–41) for Std; 18.6 (13–24) and 18% (13–23) for RIC re-
spectively. With a median follow up of 38 months, the 3 and 5-yr
OS and DFS were 56% (51–62) and 47.4 % (42–53); 49 % (43–56)
and 42% (36–48.5) respectively. We observed a significant difference
concerning 5-yr OS according to the pretransplant disease status
[CR: 73% (60–89), PR: 57% (48–68) and PD: 35% (26–46)]
(p\0.00001).There was no significant difference between std and
RIC in term of OS with 52.4 % (42–66) and 47% (40–55.5) respec-
tively (p 5 0.44) [Std and RIC Sib: 51% (37–70) and 56% (47–67);
Std and RIC UD: 60% (44–83) and 40% (29–55) respectively].
The multivariate analysis showed a significant impact of 3 factors
on OS: age: HR 5 1.061 (1.02–1.10) p\0.0001, gender: HR 5
2.29 (1.02–5.11) p 5 0.04 and PS: HR 5 3.15 (1.40–7.10) p 5
0.005.The CI of non-relapse and relapse mortality (NRM and
RM) at 3 months and 1 yr were: 10 % (7–13), 5% (3–7) and 24%
(19–28), 15% (12–19) respectively [Std:23 % (11–35.6), 6% (0–14)
1 year; RIC: 22.5% (17.5–27), 18% (13–22) at 1 year]. We showed
a high percentage of long-term OS after HSCT for CLL either after
Std or RIC without any difference between the 2 groups except
for the AGVHD and an important impact of disease status
pretransplant; age, PS and sex-matching on the global OS.15
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Host antigen presenting cells have been shown to play an impor-
tant role in triggering graft-versus-host disease (GVHD) in animal
models of allogeneic hematopoietic cell transplantation (HCT).
To determine whether kinetics of skin LC-chimerism, as assesses
by combined XY-FISH and Langerin-immunohistochemistry
among recipients of sex-mismatched grafts, are influenced by condi-
tioning-intensity in human patients, we prospectively obtained skin
biopsies before and after myeloablative (MA) and nonmyeloablative
(NMA) HCT. The conversion-kinetics of LC-chimerism were then
compared to those of dendritic cells (DC) in peripheral blood (pB)
and bone marrow (BM), and CD3 T-cells and CD56 NK-cells in
pB. Of the 28 patients analyzed, 11 had received MA conditioning
(12 Gy total body irradiation [TBI] and cyclophosphamide, n 5 5;
treosulfan and fludarabine, n 5 4; busulfan and cyclophosphamide,
n 5 2) and 17 had received NMA conditioning (2 Gy TBI
alone, n 5 2; 2 Gy TBI and fludarabine, n 5 13; 3 Gy TBI and flu-
darabine, n 5 2). All patients were transplanted for hematologic
malignancies and were given PBSC (n 5 27) or BM grafts (n 5 1)
from HLA-matched related (n 5 12) or unrelated (n 5 16) donors.
The median degree of day-28 donor LC-chimerism among all pa-
tients was 13% (range, 0–100%), which corresponded to 91%
(range, 0–100%) and 8% (0–100%) for patients given MA and
NMA conditioning, respectively (p 5 0.0008).Level of donor Langerhans cell (LC), dendritic cell (DC), T-cell
andNK-cell chimerismon day-28 after transplant according to
conditioning-intensity and tissue-compartment
Conditioning IntensityMyeloablative (n511) Non-Myeloablative (n517)% Median donor chimerism (range)Skin-LC 91 (0-100) 8 (0-100)
pB-DC 100 (90-100) 100 (93-100)
BM-DC 100 (82-100) 100 (96-100)
pB-T-cell 99 (85-100) 78 (57-100)
pB-NK-cell Not determined 100 (55-100)pB, peripheral blood; BM, bone marrow.
Only 3 of the 17 patients (18%) with NMA conditioning had day-
28 donor LC-chimerism of .50%, which corresponded to 9 of 11
patients (82%) with MA conditioning. Two of the 3 NMA transplant
recipients with.50% LC-chimerism were the only patients given 3
Gy TBI instead of the standard 2 Gy TBI. The median degrees of
day-28 donor chimerism for the other cell populations examined
were as follows: pB-DC, 100% (range, 93–100%); BM-DC, 96%
(range, 96–100%); pB-T-cells, 78% (range, 57–100%); and pB-
NK-cells, 100% (55–100%). Skin LC-chimerism levels did not cor-
relate with those of blood cell populations. In conclusion, although
circulating DCs and lymphocytes were largely donor-derived by
day-28 after transplant regardless of conditioning-intensity, LCs re-
mained predominantly host-derived after NMA conditioning. Lon-
ger follow-up is needed to determine whether kinetics of DC/LC-
chimerism may predict GVHD-characteristics and GVT-effects,
information that could be used for individualizing immunosuppres-
sive therapy and thereby lowering the toxicity of allogeneic HCT.16
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An argument can be made that a real or perceived conflict-of-
interest may arise in the situation where the same physician is
responsible for the care of two individuals whose care is interdepen-
dent. Care of donors and recipients in tissue transplantation may
represent an example. In hematopoietic stem cell transplantation
(HSCT) from unrelated donors facilitated by the National Marrow
Donor Program and in the setting of solid organ transplantation
from living donors, the standard-of-care is for donors and recipi-
ents to be under the care of separate physicians in order to provide
unbiased care and eliminate the potential for a conflict-of-interest.
However, the practice patterns of evaluation and care of related do-
nors and recipients at centers performing HSCT are unknown. Ac-
cordingly, a practice pattern survey of transplant centers in the
United States reporting to the CIBMTR was conducted by the Do-
nor Health and Safety Committee between December 2007 and
July 2008. The survey was administered as an online survey tool
sent to the center medical directors. The survey focused primarily
on determining the type of provider involved in medical clearance,
informed consent and medical management of the donor and the
relationship of that provider to the recipient. Of 258 centers sur-
veyed, 87 centers responded (33%). The median number of related
donor transplants per year at responding institutions was 16 (range:
1–115); the median total number of transplants per year was 70 (5–
450). As shown in the table, transplant physicians in no less than
70% of centers were involved in overlapping care of the donor
and the recipient during the donor evaluation, clearance and
